Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...
In its latest PFDD installment, the FDA offers a detailed roadmap for sponsors seeking to design, adapt, or validate COAs that accurately ...
View all available purchase options and get full access to this article. Supported by the National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (APP2005294) to N.D.M, Emerging ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...
Topline data to be presented Saturday, June 1, 2024 at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today ...
The report offers key market opportunities in PTSD clinical trials by providing insights into global trial distribution, enrollment trends, and prominent drugs. It aids in identifying strategic ...
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...
The Clinical Data Research Report shows data managers are currently losing an estimated 12 hours per week per study to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback